Argentina’s Laboratorio Elea Phoenix S.A. (Elea Laboratories) has initiated a proof-of-concept clinical trial with 45 patients to investigate the efficacy of ivermectin as a treatment for patients infected with SARS-CoV-2. The South American pharmaceutical company based its decision on the important Monash University lab study plus the fact that ivermectin has been widely in use for decades. Given the severity of the pandemic Elea Laboratories considers the move rational and a solid opportunity to investigate the potential given the ongoing risks associated with the COVID-19 pandemic.
TrialSite News offers a brief breakdown of this study and situation for the TrialSIte Network.
Who is Elea Laboratories?
Based in Buenos Aires, Argentina, Elea Laboratories is a biotechnology company that both invests ongoing in an internal research and development operation while also specializing in partnering with international biopharmaceutical companies to in-license promising products for development and commercialization in South America. For the latter international partnerships, the company maintains significant marketing, sales and distribution networks representing one o...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).